Allogeneic stem cell transplantation for sickle cell disease

Area of Science:

• Hematology
• Transplantation Immunology
• Genetics

Background:

• Sickle cell disease (SCD) significantly impacts patient lifespan and quality of life due to multi-organ comorbidities.
• Limited effective treatment options exist for SCD, highlighting the need for alternative therapeutic strategies.
• Advances in allogeneic hematopoietic stem cell transplantation (HSCT) safety and availability are making it a viable option for nonmalignant conditions like SCD.

Purpose of the Study:

• To review the current evidence on HSCT for sickle cell disease (SCD) across various patient populations and transplant approaches.
• To summarize outcomes from clinical trials involving HSCT for SCD.
• To discuss the unique challenges and future directions for HSCT in SCD management.

Main Methods:

• Review of published clinical trials and case studies on HSCT for SCD.
• Analysis of different graft sources, conditioning regimens, and graft-versus-host disease prophylaxis strategies.
• Synthesis of data on patient survival, graft success, and disease-related complications.

Main Results:

• Early outcomes of allogeneic HSCT for SCD are encouraging, with excellent overall survival rates observed.
• Various transplant platforms have been utilized globally, demonstrating the feasibility of HSCT in SCD.
• Graft failure has been identified as a significant challenge that needs to be addressed.

Conclusions:

• Allogeneic HSCT should be considered for severe SCD phenotypes where benefits outweigh potential complications.
• HSCT can reverse or halt end-organ damage progression in SCD patients.
• Further research is crucial to understand and mitigate graft failure and persistent pain post-transplantation in SCD recipients.